183 related articles for article (PubMed ID: 31301615)
1. Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial.
Shen Y; Zhao Q; Yu Y; Tan Y; Zhang H; Xu X; Wang Z; Li Y; Hu J; Zhong J; Li H
J Affect Disord; 2019 Oct; 257():143-149. PubMed ID: 31301615
[TBL] [Abstract][Full Text] [Related]
2. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
Ou JJ; Xun GL; Wu RR; Li LH; Fang MS; Zhang HG; Xie SP; Shi JG; Du B; Yuan XQ; Zhao JP
Psychopharmacology (Berl); 2011 Feb; 213(2-3):639-46. PubMed ID: 20340011
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
6. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
[TBL] [Abstract][Full Text] [Related]
7. Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant?
Gerra ML; Marchesi C; Amat JA; Blier P; Hellerstein DJ; Stewart JW
J Clin Psychiatry; 2014 Sep; 75(9):e939-44. PubMed ID: 25295437
[TBL] [Abstract][Full Text] [Related]
8. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder.
Leuchter AF; Lesser IM; Trivedi MH; Rush AJ; Morris DW; Warden D; Fava M; Wisniewski SR; Luther JF; Perales M; Gaynes BN; Stewart JW
J Psychiatr Pract; 2008 Sep; 14(5):271-80. PubMed ID: 18832958
[TBL] [Abstract][Full Text] [Related]
9. The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial.
Soczynska JK; Ravindran LN; Styra R; McIntyre RS; Cyriac A; Manierka MS; Kennedy SH
Psychiatry Res; 2014 Dec; 220(1-2):245-50. PubMed ID: 25124683
[TBL] [Abstract][Full Text] [Related]
10. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
Jefferson JW; Rush AJ; Nelson JC; VanMeter SA; Krishen A; Hampton KD; Wightman DS; Modell JG
J Clin Psychiatry; 2006 Jun; 67(6):865-73. PubMed ID: 16848645
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
14. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
15. An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features.
Seo HJ; Lee BC; Seok JH; Jeon HJ; Paik JW; Kim W; Kwak KP; Han C; Lee KU; Pae CU
Pharmacopsychiatry; 2013 Sep; 46(6):221-6. PubMed ID: 23963965
[TBL] [Abstract][Full Text] [Related]
16. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
Lepola U; Wade A; Andersen HF
Int Clin Psychopharmacol; 2004 May; 19(3):149-55. PubMed ID: 15107657
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.
Kim EY; Kim SH; Lee HJ; Lee NY; Kim HY; Park CHK; Ahn YM
J Affect Disord; 2019 Dec; 259():91-97. PubMed ID: 31445345
[TBL] [Abstract][Full Text] [Related]
18. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of escitalopram in treatment of severe depression in Chinese population.
Si T; Wang G; Yang F; Fang Y; Fang M; Li J; Dong J; Shen X; Zhuo J; Rui Q; Wang J; Cuili H
Metab Brain Dis; 2017 Jun; 32(3):891-901. PubMed ID: 28299626
[TBL] [Abstract][Full Text] [Related]
20. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
